Ophthalix, a clinical-stage biopharm company focused on developing therapeutic products for the treatment of ophthalmic disorders, is currently developing candidate CF101 for the treatment of three ophthalmic indications: dry eye syndrome, glaucoma, and uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: